초록 ▼

Proliferation of colorectal, gastric and esophageal cancer cells is inhibited by administering ST receptor ligand. The number of ST receptor molecules on the surface of a colorectal cell or metastasized colorectal cancer cell are increased by administering an ST receptor ligand such that ligand come

Proliferation of colorectal, gastric and esophageal cancer cells is inhibited by administering ST receptor ligand. The number of ST receptor molecules on the surface of a colorectal cell or metastasized colorectal cancer cell are increased by administering an ST receptor ligand such that ligand comes into contact with an ST receptor on the surface of the colorectal cell. Pharmaceutical compositions comprise sterile, pyrogen free ST receptor ligand and a pharmaceutically acceptable carrier or diluent. Metastasized colorectal cancer is treated or imaged by increasing the number of ST receptor molecules on the surface of a metastasized colorectal cancer cell and then administering a pharmaceutical composition containing components that target the ST receptor for delivery of a therapeutic agent or imaging agent. Methods of detecting metastasized colorectal cancer are disclosed. Methods of delivering active compounds to a colorectal cell in an individual are disclosed.

대표청구항 ▼

1. A method of treating an individual who has metastasized colorectal cancer or primary or metastasized gastric or esophageal cancer in an individual who has been identified as having metastasized colorectal cancer or primary or metastasized gastric or esophageal cancer, said method comprising the s

1. A method of treating an individual who has metastasized colorectal cancer or primary or metastasized gastric or esophageal cancer in an individual who has been identified as having metastasized colorectal cancer or primary or metastasized gastric or esophageal cancer, said method comprising the steps in the following order: a) administering to said individual a cytostatically effective amount of a guanylyl cyclase C ligand sufficient to inhibit cell proliferation by the cytostatic effect of the guanylyl cyclase C ligand for at least 6 hours wherein, wherein said guanylyl cycles C ligand activates guanylyl cyclase C on cancer cells, and stimulates accumulation of intracellular cGMP, andb) subsequently after administration of said guanylyl cycles C ligand is completed administering a therapeutically effective amount of a cytotoxic therapeutic agent or radiation,wherein effectiveness of said therapeutically effective amount of a cytotoxic therapeutic agent or radiation is enhanced by prior inhibition of proliferation of cancer cells by said cytostatically effective amount of said guanylyl cyclase C ligand. 2. The method of claim 1 wherein said cytotoxic therapeutic agent is selected from the group consisting of: methotrexate, doxorubicin, daunorubicin, cytosinarabinoside, etoposide, 5- fluorouracil, melphalan, chlorambucil, cis-platin, vindesine, mitomycin, bleomycin, purothionin, macromomycin, 1,4 benzoquinone derivatives, trenimon, ricin, ricin A chain, Pseudomonas exotoxin, diphtheria toxin, Clostridium perfringens phospholipase C, bovine pancreatic ribonuclease, pokeweed antiviral protein, abrin, abrin A chain, cobra venom factor, gelonin, saporin, modeccin, viscumin, volkensin, nitroimidazole, metronidazole and misonidazole. 3. The method of claim 1 wherein the individual has been identified as having metastatic colorectal, esophageal or stomach cancer. 4. The method of claim 1, wherein the cytostatically effective amount of a guanylyl cyclase C ligand is an amount sufficient to maintain a concentration of greater than or equal to 10 times the EC50 of said guanylyl cyclase C ligand. 5. The method of claim 1 wherein said cytotoxic therapeutic agent is a guanylyl cyclase C ligand conjugated to a cytotoxic moiety. 6. The method of claim 5 wherein said cytotoxic therapeutic agent is an anti-guanylyl cyclase C antibody conjugated to a cytotoxic moiety. 7. The method of claim 1 wherein the guanylyl cyclase C ligand that activates guanylyl cyclase C on cancer cells is administered in an amount sufficient to inhibit cell proliferation by the cytostatic effect of the guanylyl cyclase C ligand for at least 8 hours. 8. The method of claim 1 wherein the guanylyl cyclase C ligand that activates guanylyl cyclase C on cancer cells is administered in an amount sufficient to inhibit cell proliferation by the cytostatic effect of the guanylyl cyclase C ligand for at least 12 hours. 9. The method of claim 1 wherein the guanylyl cyclase C ligand that activates guanylyl cyclase C on cancer cells is administered in an amount sufficient to inhibit cell proliferation by the cytostatic effect of the guanylyl cyclase C ligand for at least 16 hours. 10. The method of claim 1 wherein the guanylyl cyclase C ligand that activates guanylyl cyclase C on cancer cells is administered in an amount sufficient to inhibit cell proliferation by the cytostatic effect of the guanylyl cyclase C ligand for at least 20 hours. 11. The method of claim 1 wherein the guanylyl cyclase C ligand that activates guanylyl cyclase C on cancer cells is administered in an amount sufficient to inhibit cell proliferation by the cytostatic effect of the guanylyl cyclase C ligand for at least 24 hours. 12. The method of claim 1 wherein said guanylyl cyclase C ligand that activates guanylyl cyclase C on cancer cells is administered intravenously. 13. The method of claim 1 wherein said guanylyl cyclase C ligand that activates guanylyl cyclase C is administered for 7-15 days followed by treatment using said cytotoxic agent. 14. The method of claim 1 wherein said guanylyl cyclase C ligand that activates guanylyl cyclase C is administered for 30 days followed by treatment using said cytotoxic agent. 15. The method of claim 1 comprising administering more than one cytotoxic agent. 16. The method of claim 1 comprising administering one cytotoxic agent that selectively kills cells in S phase and one cytotoxic drug that selectively kills cells in G1 phase. 17. The method of claim 1 wherein said cytotoxic therapeutic agent is selected from the group consisting of: methotrexate, doxorubicin, daunorubicin, cytosinarabinoside, etoposide, 5- fluorouracil, melphalan, chlorambucil, cis-platin, vindesine, mitomycin, bleomycin, purothionin, macromomycin, 1,4 benzoquinone derivatives, nitroimidazole, metronidazole and misonidazole. 18. A method of treating an individual who has metastasized colorectal cancer or primary or metastasized gastric or esophageal cancer in an individual who has been identified as having metastasized colorectal cancer or primary or metastasized gastric or esophageal cancer, said method comprising the steps in the following order: a) administering to said individual for a period sufficient to inhibit the proliferation of cancer cells, a cytostatically effective amount of a guanylyl cyclase C ligand that activate guanylyl cyclase C on cancer cells, wherein said activation of guanylyl cyclase C stimulates intracellular accumulation of cGMP and inhibits proliferation of said cancer cells; andb) subsequently after administration of said guanylyl cyclase C ligand is completed administering a therapeutically effective amount of a cytotoxic therapeutic agent or radiation;wherein effectiveness of said therapeutically effective amount of a cytotoxic therapeutic agent or radiation is enhanced by prior inhibition of proliferation of cancer cells by said cytostatically effective amount of said guanylyl cyclase C ligand. 19. The method of claim 18 wherein said cytotoxic therapeutic agent is selected from the group consisting of: methotrexate, doxorubicin, daunorubicin, cytosinarabinoside, etoposide, 5- fluorouracil, melphalan, chlorambucil, cis-platin, vindesine, mitomycin, bleomycin, purothionin, macromomycin, 1,4 benzoquinone derivatives, trenimon, ricin, ricin A chain, Pseudomonas exotoxin, diphtheria toxin, Clostridium perfringens phospholipase C, bovine pancreatic ribonuclease, pokeweed antiviral protein, abrin, abrin A chain, cobra venom factor, gelonin, saporin, modeccin, viscumin, volkensin, nitroimidazole, metronidazole and misonidazole. 20. The method of claim 18 wherein the individual has been identified as having metastatic colorectal, esophageal or stomach cancer. 21. The method of claim 18 wherein said cytotoxic therapeutic agent is a guanylyl cyclase C ligand conjugated to a cytotoxic moiety. 22. The method of claim 18 wherein said cytotoxic therapeutic agent is an anti-guanylyl cyclase C antibody conjugated to a cytotoxic moiety. 23. The method of claim 18 wherein said guanylyl cyclase C ligand that activates guanylyl cyclase C on cancer cells is administered intravenously. 24. The method of claim 18 comprising administering more than one cytotoxic agent. 25. The method of claim 18 comprising administering one cytotoxic agent that selectively kills cells in S phase and one cytotoxic drug that selectively kills cells in G1 phase. 26. The method of claim 18 wherein said cytotoxic therapeutic agent is selected from the group consisting of: methotrexate, doxorubicin, daunorubicin, cytosinarabinoside, etoposide, 5- fluorouracil, melphalan, chlorambucil, cis-platin, vindesine, mitomycin, bleomycin, purothionin, macromomycin, 1,4 benzoquinone derivatives, nitroimidazole, metronidazole and misonidazole.